To the full analysis
Nektar Therapeutics stock: growth
NKTRNektar Therapeutics reported $55.23M in revenue for fiscal 2025, down 43.9% on the prior year, down 18.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−7%
per year from 2006 to 2025, per share −11.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −18.4% | −13.3% | −7.0% |
| Revenue per share | −23.9% | −18.8% | −11.9% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $217.72M | −$154.76M | −$115.24M |
| 2007 | $273.03M | −$32.76M | $113.51M |
| 2008 | $90.19M | −$34.34M | −$164.64M |
| 2009 | $71.93M | −$102.52M | $19.04M |
| 2010 | $159.04M | −$37.94M | −$87.33M |
| 2011 | $71.48M | −$133.98M | −$123.46M |
| 2012 | $81.19M | −$171.86M | −$140.34M |
| 2013 | $148.92M | −$162.01M | −$42.62M |
| 2014 | $200.71M | −$53.92M | −$151.98M |
| 2015 | $230.78M | −$81.18M | −$84.28M |
| 2016 | $165.44M | −$153.52M | −$123.42M |
| 2017 | $307.71M | −$96.69M | −$90.09M |
| 2018 | $1.19B | $681.31M | $703.98M |
| 2019 | $114.62M | −$440.67M | −$354.97M |
| 2020 | $152.92M | −$444.44M | −$320.55M |
| 2021 | $101.91M | −$523.84M | −$427.65M |
| 2022 | $92.06M | −$368.2M | −$309.68M |
| 2023 | $90.12M | −$276.06M | −$193.47M |
| 2024 | $98.43M | −$118.96M | −$177.18M |
| 2025 | $55.23M | −$164.08M | −$208.68M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.